CorMedix Inc (CRMD):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:CorMedix Inc (CRMD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7982
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
CorMedix Inc (CorMedix) is a commercial-stage pharmaceutical company that develops and commercializes therapeutic products for prevention and treatment of cardiac, renal and infectious diseases. The company offers neutrolin, a non-antibiotic anti-infective developed as a preventative solution to decrease the threat of infection and blood clots in central venous catheters (CVCs). It offers neutrolin product, which act as novel formulation of taurolidine, citrate and heparin provides preventative solution by decreasing the triple threat of infection. CorMedix also develops therapeutic products for the prevention and treatment of inflammatory diseases. The company markets its products through its distribution network located across the US. CorMedix is headquartered in Berkeley Heights, New Jersey, the US.

CorMedix Inc (CRMD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CorMedix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
CorMedix Inc, Medical Devices Deals, 2012 to YTD 2018 10
CorMedix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
CorMedix Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
CorMedix Enters into Co-Development Agreement with POETIC for CRMD-005 12
Licensing Agreements 13
CorMedix Enters into Licensing Agreement with NanoProteagen 13
Equity Offering 14
Cormedix to Raise USD15.61 Million in Public Offering of Shares 14
CorMedix Files Registration Statement for Public Offering of Shares for up to USD70 Million 15
CorMedix Plans to Raise up to USD20 Million in Public Offering of Shares 16
CorMedix to Raise USD5 Million in Private Placement of Preferred Shares 17
CorMedix Raises USD14 Million in Public Offering of Shares and Warrants 18
CorMedix Raises USD28.45 Million in Public Offering of Shares 20
CorMedix Completes Private Placement Of Units For US$7.4 Million 21
CorMedix Completes Private Placement Of Shares For US$1.5 Million 22
CorMedix Completes Private Placement Of Shares For US$1.5 Million 24
CorMedix Announces Private Placement Of Shares For US$2 Million 26
CorMedix Files Registration Statement For Public Offering Of Securities For US$30 Million 27
Debt Offering 28
CorMedix Completes Final Tranche Of Private Placement Of Notes For US$0.5 Million 28
CorMedix Inc – Key Competitors 29
CorMedix Inc – Key Employees 30
CorMedix Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Aug 14, 2018: Cormedix reports second quarter financial results 32
May 15, 2018: Cormedix Announces First Quarter 2018 Financial Results 33
Mar 19, 2018: Cormedix Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Business Update 34
Nov 09, 2017: CorMedix Reports Third Quarter Financial Results and Provides Business Update 36
Aug 09, 2017: CorMedix Reports Second Quarter Financial Results and Provides Business Update 38
May 10, 2017: CorMedix Reports First Quarter Financial Results and Provides Business Update 40
Mar 17, 2017: Cormedix Reports fourth quarter and full year 2016 financial results and provides business update 41
Corporate Communications 42
Aug 31, 2018: CorMedix announces NYSE american acceptance of plan to regain listing compliance 42
Aug 25, 2017: CorMedix Announces a Change to its Senior Leadership 43
Aug 07, 2017: CorMedix Appoints Gary Gelbfish, M.D., to Board of Directors 44
Jun 26, 2017: Cormedix Appoints Mehmood Khan, M.D. And Steven Lefkowitz to its Board of Directors 45
Jun 12, 2017: Cormedix Announces Changes to Board of Directors 47
Mar 02, 2017: Cormedix Appoints John L. Armstrong to Senior Leadership Team 48
Feb 01, 2017: Cormedix Announces New Appointments to Senior Leadership Team 49
Product News 50
09/07/2017: CorMedix Presents Data Demonstrating Antimicrobial Activity of Taurolidine Against Potentially Deadly Fungal Pathogen Candida auris 50
Other Significant Developments 51
Feb 27, 2018: Cormedix provides update on its financing plans in connection with its ongoing lock-it 100 clinical study 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
CorMedix Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CorMedix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CorMedix Inc, Deals By Therapy Area, 2012 to YTD 2018 9
CorMedix Inc, Medical Devices Deals, 2012 to YTD 2018 10
CorMedix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
CorMedix Enters into Co-Development Agreement with POETIC for CRMD-005 12
CorMedix Enters into Licensing Agreement with NanoProteagen 13
Cormedix to Raise USD15.61 Million in Public Offering of Shares 14
CorMedix Files Registration Statement for Public Offering of Shares for up to USD70 Million 15
CorMedix Plans to Raise up to USD20 Million in Public Offering of Shares 16
CorMedix to Raise USD5 Million in Private Placement of Preferred Shares 17
CorMedix Raises USD14 Million in Public Offering of Shares and Warrants 18
CorMedix Raises USD28.45 Million in Public Offering of Shares 20
CorMedix Completes Private Placement Of Units For US$7.4 Million 21
CorMedix Completes Private Placement Of Shares For US$1.5 Million 22
CorMedix Completes Private Placement Of Shares For US$1.5 Million 24
CorMedix Announces Private Placement Of Shares For US$2 Million 26
CorMedix Files Registration Statement For Public Offering Of Securities For US$30 Million 27
CorMedix Completes Final Tranche Of Private Placement Of Notes For US$0.5 Million 28
CorMedix Inc, Key Competitors 29
CorMedix Inc, Key Employees 30
CorMedix Inc, Subsidiaries 31

List of Figures
CorMedix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CorMedix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
CorMedix Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[CorMedix Inc (CRMD):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Handok Inc (002390)-医療機器分野:企業M&A・提携分析
    Summary Handok Inc (Handok), formerly known as Handok Pharmaceuticals Co Ltd, is a pharmaceutical and health care company which develops, manufactures and distributes healthcare solutions. The company develops and provides pharmaceutical products including prescription drugs, OTC drugs, medical devi …
  • Somnomed Ltd (SOM):企業の財務・戦略的SWOT分析
    Summary Somnomed Ltd (SomnoMed) is a medical device company that develops, produces, commercializes and markets devices for the oral treatment of sleep-related disorders. The company’s products include Somnodent, an oral appliance for obstructive sleep apnea; and Somnobrux, a mouthguard that protect …
  • Curetis NV (CURE):企業の財務・戦略的SWOT分析
    Summary Curetis NV (Curetis) is a medical device company that offers molecular diagnosis solutions. The company provides diagnostic systems developed with Unyvero platform for severe infectious diseases. Its products are used in rapid diagnosis for cartridges, diseases such as implant and tissue inf …
  • Dentsu Inc (4324):企業の財務・戦略的SWOT分析
    Dentsu Inc (4324) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • C.H. Robinson Worldwide Inc (CHRW):企業の財務・戦略的SWOT分析
    C.H. Robinson Worldwide Inc (CHRW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Jiangsu Jiuding New Material Co Ltd (002201):企業の財務・戦略的SWOT分析
    Jiangsu Jiuding New Material Co Ltd (002201) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • Cox & Kings Limited:企業の戦略・SWOT・財務分析
    Cox & Kings Limited - Strategy, SWOT and Corporate Finance Report Summary Cox & Kings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • GLG Life Tech Corp (GLG):企業の財務・戦略的SWOT分析
    GLG Life Tech Corp (GLG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Hyundai Heavy Industries Co., Ltd.:企業の戦略・SWOT・財務情報
    Hyundai Heavy Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Hyundai Heavy Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Suburban Propane Partners, L.P.:企業の戦略・SWOT・財務分析
    Suburban Propane Partners, L.P. - Strategy, SWOT and Corporate Finance Report Summary Suburban Propane Partners, L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Teleflex Incorporated:戦略・SWOT・企業財務分析
    Teleflex Incorporated - Strategy, SWOT and Corporate Finance Report Summary Teleflex Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Porcelanosa Grupo AIE:企業の戦略・SWOT・財務情報
    Porcelanosa Grupo AIE - Strategy, SWOT and Corporate Finance Report Summary Porcelanosa Grupo AIE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Reliance Power Ltd (RPOWER):電力:M&Aディール及び事業提携情報
    Summary Reliance Power Ltd (RPower), formerly Reliance Energy Generation Private Limited, is a power generation and coal resources company. It develops, constructs, and operates power projects and coal mines. The company produces electricity from various sources of electricity including coal, solar …
  • Bicycle Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Bicycle Therapeutics Ltd (Bicycle Therapeutics) is a biotechnology company that develops bicyclic peptides Medicines for the treatment of cancers and other debilitating diseases. The company's proprietary bicyclic peptide technology enables systematic cyclisation of peptides and helps to ide …
  • Petrogrand AB:石油・ガス:M&Aディール及び事業提携情報
    Summary Petrogrand AB (Petrogrand), formerly Malka Oil AB is an oil and gas company that acquires, explores and produces crude oil and natural gas assets. The company carries out management and refining of Russian oil assets. It holds interests in the Nizhne-Paninsky license area located in northwes …
  • Revance Therapeutics Inc (RVNC)-医療機器分野:企業M&A・提携分析
    Summary Revance Therapeutics Inc (Revance Therapeutics) develops, manufactures and commercializes novel botulinum toxin products. The company’s product candidate includes RT002, an injectable formulation of botulinum toxin type for the treatment of glabellar lines, cervical dystonia, and plantar fas …
  • First Bancorp. (FBP):企業の財務・戦略的SWOT分析
    First Bancorp. (FBP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Twist Bioscience Corp:医療機器:M&Aディール及び事業提携情報
    Summary Twist Bioscience Corp (Twist Bioscience) is a DNA specializing and development company that develops DNA products ad DNA synthesis process. The company provides products includes DNA pools for gRNA cloning such as unamplified oligo pools, cloning-ready oligo pools; protein scanning single va …
  • Olam International Ltd:戦略・SWOT・企業財務分析
    Olam International Ltd - Strategy, SWOT and Corporate Finance Report Summary Olam International Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Nuclear Decommissioning Authority:企業の戦略的SWOT分析
    Nuclear Decommissioning Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆